Peter Atadja, a Ghanaian Drug Research and Development Scientist has led a team of researchers from Novartis Institute
for Biochemical Research to develop
Panobinostat (LBH - 589), an experimental drug
for the treatment of cancers.LBH589 is a potent oral pan-inhibitor of class I, II, and IV histone (and non-histone) deacetylase enzymes (HDACs / DACs).
Dr. Remiszewski is the co-inventor of
panobinostat (Farydak ®), which the FDA approved in February 2015
for the treatment of multiple myeloma.